A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Lupin receives US FDA approval for tobramycin inhalation solution

The product is Lupin's first generic approval in the inhalation space

BS B2B Bureau  |  Mumbai 

Lupin Limited has received final approval for its tobramycin inhalation solution (300 mg/5 ml) from the US Food and Drug Administration (FDA). The approved product is the generic version of Novartis Pharmaceuticals Corporation’s Tobi.

Lupin’s tobramycin inhalation solution is indicated for the management of cystic fibrosis patients with P. aeruginosa.

According to IMS MAT December 2016 data, tobramycin inhalation solution (300 mg/5 ml) had US sales of $ 133.6 million.

Lupin receives US FDA approval for tobramycin inhalation solution

The product is Lupin's first generic approval in the inhalation space

The product is Lupin's first generic approval in the inhalation space
Lupin Limited has received final approval for its tobramycin inhalation solution (300 mg/5 ml) from the US Food and Drug Administration (FDA). The approved product is the generic version of Novartis Pharmaceuticals Corporation’s Tobi.

Lupin’s tobramycin inhalation solution is indicated for the management of cystic fibrosis patients with P. aeruginosa.

According to IMS MAT December 2016 data, tobramycin inhalation solution (300 mg/5 ml) had US sales of $ 133.6 million.

 image
Business Standard
177 22